thorium-x and Leukemia

thorium-x has been researched along with Leukemia* in 3 studies

Other Studies

3 other study(ies) available for thorium-x and Leukemia

ArticleYear
Administration of lower doses of radium-224 to ankylosing spondylitis patients results in no evidence of significant overall detriment.
    PloS one, 2020, Volume: 15, Issue:4

    The use of low doses of radium-224 (224Ra) chloride for the treatment of ankylosing spondylitis was stopped following the discovery that patients treated with it had a higher than control incidence of leukaemia and other cancers. This was so even though the treatment resulted in decreased pain and increased mobility-both of which are associated with decreased mortality. It was decided to re-analyze the epidemiological data looking at all causes of death. The risk of leukaemia, solid cancer, death from non-cancer causes and from all causes in a study populations of men that received either the typical dose of 5.6 to 11.1 MBq of 224Ra, any dose of 224Ra or no radium were compared using the Cox proportional hazard model. For patients that received the typical dose of 224Ra agreed with the excess cancer was similar to that reported in previous studies. In contrast, these patients were less likely to die from non-cancer diseases and from all causes of death than the control patients. No excess mortality was also found in the population of all males that received the radionuclide. It is concluded that 224Ra treatment administered at low doses to patients with ankylosing spondylitis did not impact mortality from all causes. The study demonstrates the need to consider all causes of death and longevity when assessing health impacts following irradiation.

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Cause of Death; Dose-Response Relationship, Radiation; Follow-Up Studies; Humans; Injections, Intravenous; Leukemia; Male; Middle Aged; Neoplasms, Radiation-Induced; Radiotherapy Dosage; Radium; Safety-Based Drug Withdrawals; Spondylitis, Ankylosing; Thorium; Time Factors

2020
Incidence of leukaemia and other malignant diseases following injections of the short-lived alpha-emitter 224Ra into man.
    Radiation and environmental biophysics, 2009, Volume: 48, Issue:3

    We performed an epidemiological study on 1,471 ankylosing spondylitis patients treated with repeated intravenous injections of the short lived alpha-emitter (224)Ra (excluding radiation therapy with X-rays) between 1948 and 1975. These patients have been followed together with a control group of 1,324 ankylosing spondylitis patients treated neither with radioactive drugs nor with X-rays. The mean follow-up time was 26.3 years in the exposed and 24.6 years in the control group. To date, causes of death have been ascertained for 1,006 exposed patients and 1,072 controls. Special emphasis was placed on the reporting of malignant diseases. Expected numbers of cases were computed for the age, sex and calendar year distribution of both groups using cancer registry incidence rates. In the exposed group 18 cases of kidney cancer (vs. 9.1 cases expected, P < 0.01) and 4 malignant thyroid tumours (vs. 1.2 cases expected, P = 0.03) were observed. In the control group the observed cases for these tumours were not significantly elevated. The most striking observation, however, were the 21 cases of leukaemia in the exposed group (vs. 6.8 cases expected, P < 0.001) compared to 12 cases of leukaemia in the control group (vs. 7.5 cases expected). Further sub-classification of the leukaemias demonstrated a high increase of myeloid leukaemia in the exposed group (12 cases observed vs. 2.9 cases expected, P < 0.001), and out of these, especially a high excess of acute myeloid leukaemias (7 cases observed vs. 1.8 expected, P = 0.003). In the controls the observed cases are within the expected range (4 myeloid leukaemias vs. 3.1 cases). This increase in total leukaemias as well as particularly in myeloid leukaemias is significant in direct comparison between the exposed and control groups too (P < 0.05). The enhanced leukaemia incidence in the exposed group is in line with the observation of increased leukaemia incidence in mice injected with (224)Ra.

    Topics: Aged; Alpha Particles; Female; Follow-Up Studies; Half-Life; Humans; Injections; Leukemia; Male; Middle Aged; Neoplasms, Radiation-Induced; Radiotherapy Dosage; Radium; Retrospective Studies; Spondylitis, Ankylosing; Thorium; Time Factors

2009
[Plasma cell leukemia after thorium X therapy, with a contribution on the nosological position of plasma cell leukemia].
    Arztliche Wochenschrift, 1956, Dec-07, Volume: 11, Issue:49

    Topics: Humans; Leukemia; Leukemia, Plasma Cell; Radioactivity; Radium; Thorium

1956